NetworkNewsBreaks – Adaptimmune Therapeutics plc (NASDAQ: ADAP) Secures $84M in Underwritten Public Offering
Adaptimmune Therapeutics (NASDAQ: ADAP), a leader in T-cell therapy to treat cancer, has closed an underwritten public offering of 21,000,000 of its American Depositary Shares (“ADSs”). According to the update, Adaptimmune Therapeutics secured gross proceeds of $84 million in the offering, with each of the ADSs sold at the public offering price of $4.00. Adaptimmune has, in connection with the offering, granted the underwriters a 30-day option to purchase up to an additional 3,150,000 ADSs at the public offering price. All ADSs in this offering are sold by Adaptimmune Therapeutics, which intends to use the proceeds to advance the development…







